Preserving Fertility in Women With Cancer

Hoffman, Aubri; Rauh‐Hain, J. Alejandro; Woodard, Terri L.

doi:10.1001/jamaoncol.2022.4930

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian suppression using GnRHa to protect the ovarian reserve from damage induced by chemotherapy remains controversial 13,14 . This was not found to be effective by a randomized clinical trial using the ovarian reserve surrogate, anti‐Müllerian hormone, commonly used in conjunction with the antral follicle count to evaluate alterations in the ovarian reserve 15 .…”

Section: Discussionmentioning

confidence: 99%

Giving birth after fertility‐sparing treatment for primary leiomyosarcoma of the fallopian tube

Wang,

Xu,

Deng

et al. 2024

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Primary leiomyosarcoma of the fallopian tube (PLFT) is an extremely rare gynecological malignancy that has only been described in case reports. Fertility‐sparing treatment for PLFT has not been reported previously. A 24‐year‐old nulligravida woman was diagnosed with stage IC1 PLFT in the right fallopian tube after experiencing right lower quadrant pain for 2 weeks. She underwent laparoscopic right salpingectomy to preserve fertility followed by adjuvant chemotherapy with gemcitabine/docetaxel. She subsequently became pregnant spontaneously, delivering a term baby 27 months after treatment. This appears to be the only report of the use of fertility‐preserving treatment for PLFT. The success of the treatment provides valuable information on the preservation of fertility in young women with PLFT.

show abstract

Section: Discussionmentioning

confidence: 99%

Giving birth after fertility‐sparing treatment for primary leiomyosarcoma of the fallopian tube

Wang,

Xu,

Deng

et al. 2024

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The Survivorship Oncofertility Barriers Scale provides a tool to assess survivors’ multifactorial oncofertility barriers and inform tailored counseling and shared decision making. Implementation of this scale can also inform gaps in evidence and identify opportunities for addressing barriers to care that help survivors achieve their motherhood goals and improves their health outcomes 35. Given known care disparities, this scale may be of particular use in developing targeted solutions to improve equity.…”

Section: Discussionmentioning

confidence: 99%

Assessing gaps in motherhood after cancer: development and psychometric testing of the Survivorship Oncofertility Barriers Scale

Hoffman

Denham

et al. 2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveWith a growing population of young cancer survivors, there is an increasing need to address the gaps in evidence regarding cancer survivors’ obstetric outcomes, fertility care access, and experiences. As part of a large research program, this study engaged survivors and experts in co-developing and testing the validity, reliability, acceptability, and feasibility of a scale to assess survivor-reported barriers to motherhood after cancer.MethodsScale items were developed based on literature and expert review of 226 reproductive health items, and six experience and focus groups with 26 survivors of breast and gynecological cancers. We then invited 128 survivors to complete the scale twice, 48 hours apart, and assessed the scale’s psychometric properties using exploratory factor analyses including reliability, known-group validity, and convergent validity.ResultsItem development identified three primary themes: multifaceted barriers for cancer survivors; challenging decisions about whether and how to pursue motherhood; and a timely need for evidence about obstetric outcomes. Retained items were developed into a 24-item prototype scale with four subscales. Prototype testing showed acceptable internal consistency (Cronbach’s alpha=0.71) and test-retest reliability (intraclass correlation coefficient=0.70). Known-group validity was supported; the scale discriminated between groups by age (x=70.0 for patients ≥35 years old vs 54.5 for patients <35 years old, p=0.02) and years since diagnosis (x=71.5 for ≥6 years vs 54.3 for<6 years, p=0.01). The financial subscale was correlated with the Economic StraiN and Resilience in Cancer measure of financial toxicity (ρ=0.39, p<0.001). The scale was acceptable and feasibly delivered online. The final 22-item scale is organized in four subscales: personal, medical, relational, and financial barriers to motherhood.ConclusionThe Survivorship Oncofertility Barriers Scale demonstrated validity, reliability, and was acceptable and feasible when delivered online. Implementing the scale can gather the data needed to inform shared decision making and to address disparities in fertility care for survivors.

show abstract

Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United States

Pino,

Lee,

Anderson

et al. 2024

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Preserving Fertility in Women With Cancer

Abstract: This Viewpoint discusses strategies to optimize oncofertility care and improve the survivorship experience of women with cancer.

Cited by 4 publications

References 9 publications

Giving birth after fertility‐sparing treatment for primary leiomyosarcoma of the fallopian tube

Giving birth after fertility‐sparing treatment for primary leiomyosarcoma of the fallopian tube

Assessing gaps in motherhood after cancer: development and psychometric testing of the Survivorship Oncofertility Barriers Scale

Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United States

Contact Info

Product

Resources

About